Multi-omic characterization reveals a distinct molecular landscape in young-onset pancreatic cancer
Ogobuiro, I. C.; Baca, Y.; Ribeiro, J. R.; Walker, P.; Wilson, G. C.; Gulhati, P.; Marshall, J.; Shroff, R. T.; Speltzer, D.; Oberley, M.; Abbott, D. E.; Kim, H. J.; Kooby, D. A.; Maithel, S. K.; Ahmad, S. A.; Merchant, N. B.; Xiu, J.; Hosein, P. J.; Datta, J.
Show abstract
PurposeUsing a real-world database with matched genomic-transcriptomic molecular data, we sought to characterize the distinct molecular correlates underlying clinical differences between young-onset pancreatic cancer (YOPC; <50-yrs.) and average-onset pancreatic cancer (AOPC; [≥]70-yrs.) patients. MethodsWe analyzed matched whole-transcriptome and DNA sequencing data from 2430 patient samples (YOPC, n=292; AOPC, n=2138) from the Caris Life Sciences database (Phoenix, AZ). Immune deconvolution was performed using the quanTIseq pipeline. Overall survival (OS) data was obtained from insurance claims (n=4928); Kaplan-Meier estimates were calculated for age-and molecularly-defined cohorts. Significance was determined as FDR-corrected P-values (Q)<0.05. ResultsYOPC patients had higher proportions of mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H), BRCA2-mutant, and PALB2-mutant tumors compared with AOPC patients, but fewer SMAD4-, RNF43-, CDKN2A-, and SF3B1-mutant tumors. Notably, YOPC patients demonstrated significantly lower incidence of KRAS mutations compared with AOPC patients (81.3% vs. 90.9%; Q=0.004). In the KRAS-wildtype subset (n=227), YOPC tumors demonstrated fewer TP53 mutations and were more likely driven by NRG1 and MET fusions, while BRAF fusions were exclusively observed in AOPC patients. Immune deconvolution revealed significant enrichment of natural killer (NK) cells, CD8+ T cells, monocytes, and M2 macrophages in YOPC patients relative to AOPC patients, which corresponded with lower rates of HLA-DPA1 homozygosity. There was an association with improved OS in YOPC patients compared with AOPC patients with KRAS-wildtype tumors (median 16.2 [YOPC-KRASWT] vs. 10.6 [AOPC-KRASWT] months; P=0.008) but not KRAS-mutant tumors (P=0.084). ConclusionIn this large, real-world multi-omic characterization of age-stratified molecular differences in PDAC, YOPC is associated with a distinct molecular landscape that has prognostic and therapeutic implications.
Matching journals
The top 14 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Germline testing data validate inferences of mutational status for variants detected from tumor-only sequencing 90%
- Clinical activity of Mitogen-Activated Protein Kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers 90%
- 5-hydroxymethylcytosine profiling of cell-free DNA identifies bivalent genes that are prognostic of survival in high-risk neuroblastoma. 90%
Similar papers in this journal
- Proteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention 90%
- Phenotypic dissection of epithelial lineages and therapeutic manipulation of differentiation programs in human Adenoid Cystic Carcinomas 89%
- Association of immunoglobulin E levels with glioma risk and survival 89%
Similar papers in this journal
- NF2 loss malignantly transforms human pancreatic acinar cells and enhances cell fitness under environmental stress 93%
- Body mass index and adiposity influence responses to immune checkpoint inhibition in endometrial cancer 93%
- Tumor-educated Gr1+CD11b+ cells instigate breast cancer metastasis by twisting cancer cells plasticity via OSM/IL6-JAK signaling 91%
Similar papers in this journal
- Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+ T cells in the tumor microenvironment and predicts clinical outcome in early- and late-phase clinical trials 95%
- Reversible Downregulation of HLA Class I in Adenoid Cystic Carcinoma 95%
- Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.